AtheroGenics releases diabetes data

AtheroGenics has released Phase III trial data showing that the patients who did not have diabetes when beginning treatment and assigned to the AGI-1067 dosage group benefited by a 63 percent reduction in progression to new onset diabetes, compared to the patients receiving placebo. Release